Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Taysha Gene Therapies, Inc.

TSHA · Nasdaq · CIK 0001806310 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

5 Form 4 transaction lines observed in the same window
1 sales · 4 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-30 · Manning Paul B · $2.1M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Stalfort John A IIIDirector
○
Sepp-Lorenzino LauraDirector
○
Long Alison SDirector
○
Donenberg Phillip B.Director
○
Nagendran SukumarPresident and Head of R&D
▼
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-30 · Manning Paul B.

Recent Form 4 activity

0Purchases
12Sales
13Other Form 4 lines
14SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING1 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
55,020,663
Previous report
51,405,384
Avg daily volume
4,932,731
Days to cover
11.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-30Manning Paul BPurchase (P)Common Stock750,000USD 2.75USD 2,062,500SEC filing ↗
2024-06-27Manning Paul BPurchase (P)Common Stock1,333,333USD 2.25USD 2,999,999SEC filing ↗
2023-11-17Manning Paul BPurchase (P)Common Stock100,000USD 1.63USD 163,000SEC filing ↗
2023-08-16Stalfort John A IIIPurchase (P)Common Stock388,889USD 0.90USD 350,000SEC filing ↗
2023-08-16Nolan Sean P.Purchase (P)Common Stock444,444USD 0.90USD 400,000SEC filing ↗
2023-08-16Manning Paul BPurchase (P)Common Stock16,466,667USD 0.90USD 14,820,000SEC filing ↗
2023-08-16Donenberg Phillip B.Purchase (P)Common Stock111,111USD 0.90USD 100,000SEC filing ↗
2023-05-16Nagendran SukumarPurchase (P)Common Stock5,000USD 0.68USD 3,400SEC filing ↗
2022-10-31Manning Paul BPurchase (P)Common Stock1,500,000USD 2.00USD 3,000,000SEC filing ↗
2022-02-03Manning Paul BPurchase (P)Common Stock76,602USD 7.84USD 600,560SEC filing ↗
2022-02-02Manning Paul BPurchase (P)Common Stock125,000USD 7.77USD 971,250SEC filing ↗
2022-02-02Nagendran SukumarPurchase (P)Common Stock10,000USD 8.01USD 80,100SEC filing ↗
2022-02-02Donenberg Phillip B.Purchase (P)Common Stock3,000USD 7.78USD 23,340SEC filing ↗
2021-11-24Manning Paul BPurchase (P)Common Stock2,202USD 13.19USD 29,044SEC filing ↗
2021-11-23Session R.A. IIPurchase (P)Common Stock42,518USD 12.44USD 529,102SEC filing ↗

Form 4 evidence

25 transaction lines in the latest 365-day window; 109 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-10Nagendran SukumarSale (S)Common Stock200,000USD 6.24USD 1,248,000SEC filing ↗
2026-06-01Stalfort John A IIIAward / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
2026-06-01Sepp-Lorenzino LauraAward / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (23 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-10Nagendran SukumarSale (S)Common Stock200,000USD 6.24USD 1,248,000SEC filing ↗
2026-06-01Stalfort John A IIIAward / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
2026-06-01Sepp-Lorenzino LauraAward / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
2026-06-01Long Alison SAward / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
2026-06-01Donenberg Phillip B.Award / grant (A)Common Stock21,335USD 0.00USD 0SEC filing ↗
2026-04-10Nagendran SukumarSale (S)Common Stock200,000USD 4.46USD 892,000SEC filing ↗
2026-04-10Nagendran SukumarOption exercise / conversion (M)Common Stock19,021USD 1.71USD 32,526SEC filing ↗
2026-02-04Alam KamranSale (S)Common Stock1,655USD 4.52USD 7,481SEC filing ↗
2026-01-26Nolan Sean P.Sale (S)Common Stock41,312USD 4.61USD 190,448SEC filing ↗
2026-01-26Nagendran SukumarSale (S)Common Stock26,918USD 4.61USD 124,092SEC filing ↗
2026-01-26Alam KamranSale (S)Common Stock23,849USD 4.61USD 109,944SEC filing ↗
2026-01-23Nolan Sean P.Sale (S)Common Stock136,789USD 4.75USD 649,748SEC filing ↗
2026-01-23Nagendran SukumarSale (S)Common Stock89,132USD 4.75USD 423,377SEC filing ↗
2026-01-23Alam KamranSale (S)Common Stock78,968USD 4.75USD 375,098SEC filing ↗
2026-01-12Nolan Sean P.Award / grant (A)Common Stock1,008,000USD 0.00USD 0SEC filing ↗
2026-01-12Nagendran SukumarSale (S)Common Stock200,000USD 4.71USD 942,000SEC filing ↗
2026-01-12Nagendran SukumarOption exercise / conversion (M)Common Stock200,000USD 1.15USD 229,563SEC filing ↗
2026-01-12Nagendran SukumarAward / grant (A)Common Stock427,000USD 0.00USD 0SEC filing ↗
2026-01-12Alam KamranAward / grant (A)Common Stock359,000USD 0.00USD 0SEC filing ↗
2025-12-01Nagendran SukumarSale (S)Common Stock260,047USD 4.51USD 1,172,812SEC filing ↗
2025-12-01Nagendran SukumarOption exercise / conversion (M)Common Stock260,047USD 1.71USD 444,680SEC filing ↗
2025-11-28Nagendran SukumarSale (S)Common Stock110,125USD 4.75USD 523,094SEC filing ↗
2025-11-28Nagendran SukumarOption exercise / conversion (M)Common Stock110,125USD 1.07USD 117,440SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerTSHA
CIK0001806310
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history109 transaction lines from 2020-09-23 to 2026-07-10
22 P purchase lines · 43 S sale lines · 44 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.